SEQSTER has announced the launch of 1-Click Eligibility™, an artificial intelligence-powered solution designed to improve the speed and accuracy of patient identification for clinical trials. The tool addresses a longstanding bottleneck in drug development, where delays in patient recruitment continue to hinder trial timelines and outcomes.
Clinical trial enrollment remains a significant industry challenge, with nearly 80% of trials failing to meet enrollment deadlines. Traditional screening processes are often manual, time-intensive, and limited in scope. SEQSTER’s solution aims to streamline this process by enabling research teams to input trial criteria in natural language and rapidly identify suitable candidates from large patient populations.
The platform leverages longitudinal, patient-consented health data aggregated across SEQSTER’s network. Using AI, it evaluates patient eligibility and ranks candidates based on confidence scores derived from data completeness and recency. Identified patient records are then converted into FDA-compliant, research-ready formats, with identifiable information shared only after appropriate consent is obtained.
“Too many patients miss out on the opportunity to participate in clinical trials simply because researchers can’t find them,” said Ardy Arianpour, CEO & Co-Founder of SEQSTER. “With 1-Click Eligibility, that no longer has to be the case.”
Early deployments have demonstrated measurable impact. In one implementation with a pharmaceutical partner, the platform screened more than 10,000 patients and identified eligible participants in under an hour. This enabled the research team to accelerate trial timelines by approximately six months.
The solution is part of SEQSTER’s broader 1-Click Solution Suite and builds on its existing infrastructure, which integrates and standardizes patient-consented health data into unified longitudinal records. With access to data from approximately 150 million patients, the platform supports a wide range of stakeholders, including life sciences companies, healthcare providers, and AI developers.
“Too many patients miss out on the opportunity to participate in clinical trials simply because researchers can’t find them,” added Ardy Arianpour. “With 1-Click Eligibility, that no longer has to be the case. We look forward to continuing our work with sponsors across the ecosystem to move studies forward faster, improve trial diversity, and ensure more patients have the opportunity to contribute to potentially life-changing research.”
The launch reflects broader industry efforts to apply AI and real-world data to improve trial efficiency, enhance diversity in recruitment, and accelerate the development of new therapies.
Click here for the original news story.